Sanofi U.S. Services, INC.

Multinational Pharmaceutical Company.

Based in DC

🤖

AI Overview

With $1.4M in lobbying spend across 23 quarterly filings, Sanofi U.S. Services, INC. is a significant lobbying presence.

$1.4M

Total Lobbying Spend

Quarterly Filings

Lobbying Firms Used

Individual Lobbyists

Spending by Year

Year	Lobbying Spend
2019	$100K
2020	$120K
2021	$180K
2022	$240K
2023	$240K
2024	$240K
2025	$240K

Lobbying Firms

MARSHALL & POPP, LLC

What They Lobby For

Healthcare policy issues as they relate to the pharmaceutical industry including research and development, pricing, value and reimbursement. Corporate tax issues.
Patents and protection of intellectual property issues, including S.1416: Affordable Prescriptions for Patients Act of 2019.
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19: Lower Costs, More Cures Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index.
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Issues related to supply chain and Buy America requirements. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic.
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Issues related to supply chain and Buy America requirements. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic, including H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, and S.4775: Delivering Immediate Relief to America's Families, Schools and Small Businesses Act. H.R.133 [116th]: Consolidated Appropriations Act, 2021.
Issues related to protection of intellectual property.
Issues related to prescription drug value, supply chains, 340B, and the COVID-19 pandemic, including: *S.Con.Res. 5, fiscal year 2021 budget resolution. *H.R.1319: American Rescue Plan Act of 2021.
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and S.1260, the United States Innovation and Competition Act.